Summary:
- The article discusses recent breakthroughs in CRISPR-Cas9 gene-editing technology, specifically focusing on the development of "prime editing" to correct pathogenic genetic mutations with higher precision and fewer off-target effects.
- It highlights the potential clinical applications of these advancements in treating hereditary blood disorders and neurodegenerative conditions, while emphasizing the necessity for rigorous ethical oversight and long-term safety studies in human trials.